AN INTERNATIONAL, PHASE II, MULTI-SITE, OPEN-LABEL, RANDOMIZED STUDY OF ALDES

ALDES 的国际、II 期、多中心、开放标签、随机研究

• 批准号: 7717048
• 负责人: DANIEL W NIXON
• 金额: $ 13.33万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-12-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7717048
• 关键词: CD4 Positive T Lymphocytes; Cells; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Highly Active Antiretroviral Therapy; Infection; Institution; International; Label; Lymphocyte Count; Patients; Phase; Purpose; Randomized; Recombinant Interleukin-2; Research; Research Personnel; Resources; Site; Source; United States National Institutes of Health; subcutaneous

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the effects of subcutaneous (SC) recombinant interleukin-2 (rIL-2) administered with and without concomitant peri cycle highly active antiretroviral therapy (HAART) to no therapy on CD4+ T lymphocyte count in patients with HIV-l infection and CD4+ T lymphocyte count ~300 cells/mm3.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这项研究的目的是将皮下（SC）重组白介素2（RIL-2）进行比较，在有或没有伴随的痛苦周期的高度活性抗逆转录病毒治疗（HAART）与CD4+ T淋巴细胞计数的NO疗法对HIV-L感染和CD4+ T Lymphocyte Counter Counter/MMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMMM。